← SynDRA
KO-143
SynDRA canonical compound SYN0087449 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | ABCG2 |
|---|
| Mechanism of action | Breast cancer resistance protein inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- Breast cancer resistance protein inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ALOX15
- KDM4E
- TDP1
- SMPD1
- SMAD3
- PTH1R
- MAPT
- KMT2A
- IDH1
- ATAD5
- HSD17B10
- GLP1R
- GBA1
- GAA
- CGA
- ATXN2
- TP53
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- BARD1
- BRCA1
- DRD3
- IL1B
- KCNJ3
- KCNJ6
- MDM2
- MDM4
- MDR1
- MLP3A
- NPY1R
- NPY2R
- PE2R2
Cross-references
Synonyms
- Ko 143
- Ko143
- Ko143 cpd
- RefChem:151339
- DTXCID50388901
- Ko143 hydrate
- C26H35N3O5
- MFCD11042273
- orb1296146
- SCHEMBL16645259
- SCHEMBL30395014
- CHEBI:95026
- GTPL10007
- EX-A745
- GLXC-07396
- Ko 143?
- LSM-6260
- LTA05493
- BDBM50305083
- MFCD19053160
- s7043
- AKOS016005202
- CS-0298
- NCGC00378799-07
- AS-77372
- HY-10010
- BRD-K64642496-001-01-6
- BRD-K64642496-001-03-2
- I3O
- (3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester
- SCHEMBL5696166
- BDBM50615469
- HMS3740M21
Look up KO-143 in the interactive SynDRA portal →